Xiaolong Jiao
YOU?
Author Swipe
View article: Mycoplasma bovis Invades Non-Phagocytic Cells by Clathrin-Dependent Endocytic Pathways and Escapes from Phagocytic Vesicles
Mycoplasma bovis Invades Non-Phagocytic Cells by Clathrin-Dependent Endocytic Pathways and Escapes from Phagocytic Vesicles Open
Mycoplasma bovis (M. bovis) is capable of causing pneumonia, arthritis, mastitis, and various other ailments in cattle of all age groups, posing a significant threat to the healthy progression of the worldwide cattle industry. The invasion…
View article: Calibrating Observational Health Record Data Against a Randomized Trial
Calibrating Observational Health Record Data Against a Randomized Trial Open
Importance The conditions required for health record data sources to accurately assess treatment effectiveness remain unclear. Emulation of randomized clinical trials (RCTs) with health record data and subsequent calibration of the results…
View article: Real-world dosing of regorafenib and outcomes among patients with metastatic colorectal cancer: a retrospective analysis using US claims data
Real-world dosing of regorafenib and outcomes among patients with metastatic colorectal cancer: a retrospective analysis using US claims data Open
Background The randomized, dose-optimization, open-label ReDOS study in US patients with metastatic colorectal cancer (CRC) showed that, compared with a standard dosing approach, initiating regorafenib at 80 mg/day and escalating to 160 mg…
View article: The Aetion Coalition to Advance Real‐World Evidence through Randomized Controlled Trial Emulation Initiative: Oncology
The Aetion Coalition to Advance Real‐World Evidence through Randomized Controlled Trial Emulation Initiative: Oncology Open
Legislative and technological advancements over the past decade have given rise to the proliferation of healthcare data generated from routine clinical practice, often referred to as real‐world data (RWD). These data have piqued the intere…
View article: Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study) Open
Background The real-world EPIX study was conducted to gather information about the characteristics of patients with metastatic castration-resistant prostate cancer (mCRPC) who survived ≥2 years after treatment with the alpha-emitter radium…
View article: Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes project
Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes project Open
View article: Real-World Outcomes of Second Novel Hormonal Therapy or Radium-223 Following First Novel Hormonal Therapy for mCRPC
Real-World Outcomes of Second Novel Hormonal Therapy or Radium-223 Following First Novel Hormonal Therapy for mCRPC Open
Aim: To evaluate real-world clinical outcomes of radium-223 or alternative novel hormonal therapy (NHT) following first-line NHT for metastatic castration-resistant prostate cancer (mCRPC). Patients & methods: Retrospective a…
View article: Modeling the Incentive Mechanism of Information Sharing in a Dual-Channel Supply Chain
Modeling the Incentive Mechanism of Information Sharing in a Dual-Channel Supply Chain Open
Information sharing is the premise of the stable operation and win-win cooperation of the dual-channel agricultural supply chain. To arouse the enthusiasm of information sharing, this paper studies the incentive mechanism of information sh…
View article: TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting
TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting Open
Although the hazard ratio for overall survival suggested a higher risk of death for patients with NTRK gene fusions, the difference was not statistically significant. Co-occurrence of NTRK gene fusions and other actionable biomarkers was u…
View article: Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer Open
View article: Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States
Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States Open
View article: Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer Open
Dose delays, dose reductions, and reduced RDI were common, and dose delays ≥ 7 days and high RDI were significantly associated with decreased mortality. These results can help identify potential risk factors and characterize the effect of …
View article: Risk Factors, Health Care Resource Utilization, and Costs Associated with Nonadherence to Antiretrovirals in Medicaid-Insured Patients with HIV
Risk Factors, Health Care Resource Utilization, and Costs Associated with Nonadherence to Antiretrovirals in Medicaid-Insured Patients with HIV Open
This study was supported by Janssen Scientific Affairs, which was involved in the study design, data collection, data analysis, manuscript preparation, and publication decisions. Emond, Lafeuille, Romdhani, and Lefebvre are employees of An…
View article: Predictors of Long-Term Response With Pazopanib in Patients With Advanced Renal-Cell Carcinoma
Predictors of Long-Term Response With Pazopanib in Patients With Advanced Renal-Cell Carcinoma Open
In aRCC patients treated with first-line pazopanib, 22% had a long-term response. Significant predictors of long-term response included an ECOG PS of 0 and a history of nephrectomy.
View article: Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer
Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer Open
Dose delays, dose reductions, and reduced RDI were common. In advanced breast cancer, health status and triple-negative disease were significantly associated with mortality. In advanced ovarian cancer, dose reductions and tumor histology w…
View article: Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers
Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers Open
Axitinib usage patterns were consistent with the National Comprehensive Cancer Network Guidelines®. Ease of use among community oncologists and patient tolerance are key features of axitinib.
View article: HER2-Positive Metastatic Breast Cancer Patients Receiving Pertuzumab in a Community Oncology Practice Setting: Treatment Patterns and Outcomes
HER2-Positive Metastatic Breast Cancer Patients Receiving Pertuzumab in a Community Oncology Practice Setting: Treatment Patterns and Outcomes Open
View article: P2.03a-008 Relative Dose Intensity of First-Line Chemotherapy and Overall Survival in Patients With Advanced Non–Small-Cell Lung Cancer (NSCLC)
P2.03a-008 Relative Dose Intensity of First-Line Chemotherapy and Overall Survival in Patients With Advanced Non–Small-Cell Lung Cancer (NSCLC) Open